Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment

Background: Atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) every 3 weeks (AtezBev) became a standard-of-care first-line treatment for advanced hepatocellular carcinoma (aHCC) following IMbrave150. However, real-world data suggest milder efficacy. Early bevacizumab interruption due to adverse eve...

Full description

Saved in:
Bibliographic Details
Main Authors: F. Rossari, D. Lavacchi, E. Alimenti, C. Soldà, F. Salani, L. Esposito, S. Foti, S. Camera, M. Persano, F. Lo Prinzi, F. Vitiello, E. Pellegrini, M. Bruccoleri, M.D. Rizzato, M. Caccese, I.G. Rapposelli, A. Guidolin, A. De Rosa, L. Antonuzzo, G. Masi, M.A. Iavarone, S. Lonardi, M. Rimini, A. Casadei-Gardini
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:ESMO Gastrointestinal Oncology
Subjects:
HCC
atezolizumab
bevacizumab
immunotherapy
dose modification
Online Access:http://www.sciencedirect.com/science/article/pii/S294981982500055X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items